{"id":3179,"date":"2022-03-08T13:53:31","date_gmt":"2022-03-08T10:23:31","guid":{"rendered":"https:\/\/iiccim.ir\/fonti-inglesi-e-francesi-accordo-piu-vicino-nel-negoziato-sul-nucleare-iraniano-2\/"},"modified":"2022-03-12T15:05:04","modified_gmt":"2022-03-12T11:35:04","slug":"pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia","status":"publish","type":"post","link":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/","title":{"rendered":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia)"},"content":{"rendered":"

Pfizer fa il pieno di vendite, ma licenzia in Italia. Nel 2019, l\u2019ultimo anno senza Covid, ha fatturato 51,7 miliardi di dollari. Quest\u2019anno i ricavi saranno quasi il doppio e, soprattutto, per oltre la met\u00e0 saranno realizzati grazie ai trattamenti anti-Covid. A dare notizia del balzo dei conti \u00e8 la stessa azienda, che ha annunciato le stime del 2022: i ricavi sono previsti tra 98 e 102 miliardi di dollari, con i vaccini e le cure per il Covid che rappresenteranno una fetta di 54 miliardi. Anche il 2021 \u00e8 andato a gonfie vele. Pfizer ha annunciato oggi (8 febbraio) di aver chiuso il quarto trimestre 2021 con ricavi a 23,84 miliardi, di cui 12,5 miliardi dai vaccini. Una cifra sotto le attese, visto che gli analisti si aspettavano ricavi a 24,12 miliardi, ma a sorprendere positivamente \u00e8 stato l\u2019utile, salito a 3,4 miliardi, che ha battuto le aspettative.
\nVaccino e pillola anti-Covid
\nDunque, grazie ai trattamenti anti-Covid, il gruppo guidato dal greco Albert Bourla nel giro di tre anni ha raddoppiato il business. Pfizer, insieme alla tedesca BioNTech, ha richiesto l\u2019autorizzazione all\u2019uso di emergenza del suo vaccino Covid-19 per bambini sotto i 5 anni alla Food and Drug Administration all\u2019inizio di questo mese. Pfizer ha anche sviluppato una pillola antivirale, chiamata Paxlovid, che pu\u00f2 essere utilizzata per curare i pazienti affetti da Covid-19 a casa prima che si ammalino gravemente. La Food and Drug Administration ha approvato Paxlovid a dicembre. Pfizer ha dichiarato che prevede di generare 22 miliardi di dollari di vendite da Paxlovid nel 2022. Gli analisti si aspettavano un fatturato di quasi 23 miliardi di dollari.
\nI numeri non hanno soddisfatto il mercato, tanto che il titolo – balzato del 60% del 2021 – \u00e8 in calo a New York.<\/p>\n","protected":false},"excerpt":{"rendered":"

Pfizer fa il pieno di vendite, ma licenzia in Italia. Nel 2019, l\u2019ultimo anno senza Covid, ha fatturato 51,7 miliardi di dollari. Quest\u2019anno i ricavi saranno quasi il doppio e, soprattutto, per oltre la met\u00e0 saranno realizzati grazie ai trattamenti anti-Covid. A dare notizia del…<\/p>\n","protected":false},"author":473,"featured_media":3181,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[162],"tags":[],"yoast_head":"\nPfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627\" \/>\n<meta property=\"og:description\" content=\"Pfizer fa il pieno di vendite, ma licenzia in Italia. Nel 2019, l\u2019ultimo anno senza Covid, ha fatturato 51,7 miliardi di dollari. Quest\u2019anno i ricavi saranno quasi il doppio e, soprattutto, per oltre la met\u00e0 saranno realizzati grazie ai trattamenti anti-Covid. A dare notizia del...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/\" \/>\n<meta property=\"og:site_name\" content=\"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-08T10:23:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-12T11:35:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1913\" \/>\n\t<meta property=\"og:image:height\" content=\"1075\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u062a\u062d\u0631\u06cc\u0631\u06cc\u0647\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/iiccim.ir\/#organization\",\"name\":\"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627 - IICCIM\",\"url\":\"https:\/\/iiccim.ir\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/iiccim.ir\/#logo\",\"inLanguage\":\"it-IT\",\"url\":\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/07\/\u0641\u0627\u0631\u0633\u06cc-\u0644\u0648\u06af\u0648.png\",\"contentUrl\":\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/07\/\u0641\u0627\u0631\u0633\u06cc-\u0644\u0648\u06af\u0648.png\",\"width\":1417,\"height\":1417,\"caption\":\"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627 - IICCIM\"},\"image\":{\"@id\":\"https:\/\/iiccim.ir\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/iiccim.ir\/#website\",\"url\":\"https:\/\/iiccim.ir\/\",\"name\":\"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627\",\"description\":\"\u0633\u0627\u06cc\u062a \u0631\u0633\u0645\u06cc \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 - \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627\",\"publisher\":{\"@id\":\"https:\/\/iiccim.ir\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/iiccim.ir\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage\",\"inLanguage\":\"it-IT\",\"url\":\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg\",\"contentUrl\":\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg\",\"width\":1913,\"height\":1075},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage\",\"url\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/\",\"name\":\"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627\",\"isPartOf\":{\"@id\":\"https:\/\/iiccim.ir\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage\"},\"datePublished\":\"2022-03-08T10:23:31+00:00\",\"dateModified\":\"2022-03-12T11:35:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u062e\u0627\u0646\u0647\",\"item\":\"https:\/\/iiccim.ir\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia)\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage\"},\"author\":{\"@id\":\"https:\/\/iiccim.ir\/#\/schema\/person\/67dfab351d2787c2413b9c681270c8c0\"},\"headline\":\"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia)\",\"datePublished\":\"2022-03-08T10:23:31+00:00\",\"dateModified\":\"2022-03-12T11:35:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage\"},\"wordCount\":292,\"publisher\":{\"@id\":\"https:\/\/iiccim.ir\/#organization\"},\"image\":{\"@id\":\"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg\",\"articleSection\":[\"Italiano\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/iiccim.ir\/#\/schema\/person\/67dfab351d2787c2413b9c681270c8c0\",\"name\":\"\u062a\u062d\u0631\u06cc\u0631\u06cc\u0647\",\"url\":\"https:\/\/iiccim.ir\/it\/author\/vasmaghi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/","og_locale":"it_IT","og_type":"article","og_title":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","og_description":"Pfizer fa il pieno di vendite, ma licenzia in Italia. Nel 2019, l\u2019ultimo anno senza Covid, ha fatturato 51,7 miliardi di dollari. Quest\u2019anno i ricavi saranno quasi il doppio e, soprattutto, per oltre la met\u00e0 saranno realizzati grazie ai trattamenti anti-Covid. A dare notizia del...","og_url":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/","og_site_name":"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","article_published_time":"2022-03-08T10:23:31+00:00","article_modified_time":"2022-03-12T11:35:04+00:00","og_image":[{"width":1913,"height":1075,"url":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"\u062a\u062d\u0631\u06cc\u0631\u06cc\u0647","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/iiccim.ir\/#organization","name":"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627 - IICCIM","url":"https:\/\/iiccim.ir\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"https:\/\/iiccim.ir\/#logo","inLanguage":"it-IT","url":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/07\/\u0641\u0627\u0631\u0633\u06cc-\u0644\u0648\u06af\u0648.png","contentUrl":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/07\/\u0641\u0627\u0631\u0633\u06cc-\u0644\u0648\u06af\u0648.png","width":1417,"height":1417,"caption":"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627 - IICCIM"},"image":{"@id":"https:\/\/iiccim.ir\/#logo"}},{"@type":"WebSite","@id":"https:\/\/iiccim.ir\/#website","url":"https:\/\/iiccim.ir\/","name":"\u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","description":"\u0633\u0627\u06cc\u062a \u0631\u0633\u0645\u06cc \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 - \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","publisher":{"@id":"https:\/\/iiccim.ir\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/iiccim.ir\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"it-IT"},{"@type":"ImageObject","@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage","inLanguage":"it-IT","url":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg","contentUrl":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg","width":1913,"height":1075},{"@type":"WebPage","@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage","url":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/","name":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia) - \u0627\u062a\u0627\u0642 \u0645\u0634\u062a\u0631\u06a9 \u0627\u06cc\u0631\u0627\u0646 \u0648 \u0627\u06cc\u062a\u0627\u0644\u06cc\u0627","isPartOf":{"@id":"https:\/\/iiccim.ir\/#website"},"primaryImageOfPage":{"@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage"},"datePublished":"2022-03-08T10:23:31+00:00","dateModified":"2022-03-12T11:35:04+00:00","breadcrumb":{"@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u062e\u0627\u0646\u0647","item":"https:\/\/iiccim.ir\/it\/"},{"@type":"ListItem","position":2,"name":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia)"}]},{"@type":"Article","@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#article","isPartOf":{"@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage"},"author":{"@id":"https:\/\/iiccim.ir\/#\/schema\/person\/67dfab351d2787c2413b9c681270c8c0"},"headline":"Pfizer: 100 miliardi di ricavi nel 2022 grazie a vaccino e cure anti-Covid (ma licenzia in Italia)","datePublished":"2022-03-08T10:23:31+00:00","dateModified":"2022-03-12T11:35:04+00:00","mainEntityOfPage":{"@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#webpage"},"wordCount":292,"publisher":{"@id":"https:\/\/iiccim.ir\/#organization"},"image":{"@id":"https:\/\/iiccim.ir\/it\/pfizer-100-miliardi-di-ricavi-nel-2022-grazie-a-vaccino-e-cure-anti-covid-ma-licenzia-in-italia\/#primaryimage"},"thumbnailUrl":"https:\/\/iiccim.ir\/wp-content\/uploads\/2022\/03\/6-1-Copy-7.jpg","articleSection":["Italiano"],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/iiccim.ir\/#\/schema\/person\/67dfab351d2787c2413b9c681270c8c0","name":"\u062a\u062d\u0631\u06cc\u0631\u06cc\u0647","url":"https:\/\/iiccim.ir\/it\/author\/vasmaghi\/"}]}},"_links":{"self":[{"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/posts\/3179"}],"collection":[{"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/users\/473"}],"replies":[{"embeddable":true,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/comments?post=3179"}],"version-history":[{"count":0,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/posts\/3179\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/media\/3181"}],"wp:attachment":[{"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/media?parent=3179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/categories?post=3179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iiccim.ir\/it\/wp-json\/wp\/v2\/tags?post=3179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}